Usana (USNA) recently conducted a clinical study on its Celavive Resurfacing Serum to evaluate the efficacy and tolerance of the product. The results showed that Resurfacing Serum was well-tolerated by all subjects and users showed statistically significant improvements in the appearance of their skin in just two weeks.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on USNA:
- USANA Health Sciences Faces Market Risk with Uncertain Hiya Acquisition Benefits
- USANA Health Sciences Earnings Call Highlights Growth and Strategic Moves
- USANA Health Sciences Reports 2024 Earnings and 2025 Outlook
- USANA Health Acquires Hiya Health to Boost Growth
- Usana reports Q4 adjusted EPS 64c, two estimates 49c